All posts by U.S. Stem Cell, Inc

U.S. Stem Cell, Inc. Reports Positive Results for Q3 2016

Sunrise, FL – November 9, 2016 – U.S. STEM CELL, INC., a Florida corporation and leader in novel regenerative medicine solutions and physician-based stem cell therapies to human and animal patients, is pleased to highlight the following results from operations for the quarter ending September 30, 2016:

• Current liabilities down $734,000 or 9.5% from $7.69M in Q3 2015 to $6.96M in Q3 2016
• Revenue up by 31% to from $557,000 in Q3 2015 to $729,000 in Q3 2016
• Net loss improved 17% from $264,000 in Q3 2015 to $219,000 in Q3 2016
• Cash used in operating activities down $322,000 or 84% from $384,000 in Q3 2015 to $62,000 in Q3 2016

“U.S. Stem Cell, Inc. continues to surpass its quarter-over-quarter business and financial performance,” stated Mike Tomas, President and CEO of U.S. Stem Cell Inc. “This is our best year yet so far. We have become a world leader in the research of new treatments for patients with degenerative conditions and continue to develop novel protocols for their care. This passion moves us to continue to work hard to strengthen the health of our business and expand our care to more countries and more patients in need.”

Operating results for the three and six months ended September 30, 2016 are not necessarily indicative of the results that can be expected for the year ending December 31, 2016.

VIEW PDF HERE

About U.S. Stem Cell, Inc.

 

US Stem Cell, Inc. (formerly Bioheart, Inc.) is an emerging enterprise in the regenerative medicine / cellular therapy industry. We are focused on the discovery, development and commercialization of cell based therapeutics that prevent, treat or cure disease by repairing and replacing damaged or aged tissue, cells and organs and restoring their normal function. We believe that regenerative medicine / cellular therapeutics will play a large role in positively changing the natural history of diseases ultimately, we contend, lessening patient burdens as well as reducing the associated economic impact disease imposes upon modern society.

 

Our business, which includes three operating divisions (US Stem Cell Training, Vetbiologics and US Stem Cell Clinic) includes the development of proprietary cell therapy products as well as revenue generating physician and patient based regenerative medicine / cell therapy training services, cell collection and cell storage services, the sale of cell collection and treatment kits for humans and animals, and the operation of a cell therapy clinic. Management maintains that revenues and their associated cash in-flows generated from our businesses will, over time, provide funds to support our clinical development activities as they do today for our general business operations. We believe the combination of our own therapeutics pipeline combined with our revenue generating capabilities provides the Company with a unique opportunity for growth and a pathway to profitability.

 

Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate”, or “continue”, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Also, forward-looking statements represent our management’s beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

The Company is subject to the risks and uncertainties described in its filings with the Securities and Exchange Commission, including the section entitled “Risk Factors” in its Annual Report on Form 10-K for the year ended December 31, 2015, and its Quarterly Reports on Form 10-Q.

 

Read More

CEO Blog: A Look at U.S. Stem Cell, Inc.’s Clinical, Educational, and Therapeutic Success in 2016

Dear shareholders and friends,

2016 has been a year of great success: U.S. Stem Cell, Inc.’s adipose treatments have been used to treat more than 6000 patients so far, and we continue to research and develop therapies and protocols to benefit others suffering from degenerative diseases that affect their tissues, cells, organs, and bodily functions.

Technology is the best communicator for our scientific advances. On July 8th, Dave Asprey of Bulletproof shared the world’s first live stream of a stem cell procedure, featuring our very own Kristin Comella and Michelle Parlo at U.S. Stem Cell Clinic. You can view the recorded livestream at U.S. Stem Cell Clinic’s Facebook page: https://www.facebook.com/usstemcellclinic/posts/1200333253332375

During August, our stem cell therapies made their way to the Rio Olympics! Dr. Scott Greenberg, a Sports Medicine and Regenerative Orthopedics specialist, took a training course through our U.S. Stem Cell Training division. With the experience and knowledge he gained, Dr. Greenberg was able to use our Platelet Rich Plasma, or “PRP” method to treat Olympic Gymnast Laurie Hernandez at this year’s 2016 Rio Olympics — just seven weeks before she was to perform on the Olympic stage! Dr. Greenberg commented, “[the platelets] forced [her leg] to heal.” Watch Dr. Greenberg discuss PRP: https://youtu.be/gvkqGPkPmiA

Then, in September, Chief Scientific Officer, Kristin Comella, was invited to speak at RAAD (Revolution Against Aging and Death) Fest where life extension enthusiasts come together to learn about the latest scientific advancements and gain vital insight into how to extend health and wellbeing. Kristin spoke about the power and future of stem cells in physician education, animal health, personal medicine, and prescription therapeutics. Her full presentation is available online here: https://youtu.be/H4T6WReGPro

We also continue to make progress in our animal health division, and just last month treated our first victim of an alligator attack at VetBiologics. The canine affected was at severe risk for infection due to a bad gator bite. After surgery and multiple stem cell doses, the patient has healed and made a complete recovery — to the joy of his owners.

At U.S. Stem Cell Clinic, we have had amazing success in our treatments of Traumatic Brain Injury (TBI) and Multiple Sclerosis (MS) this year.

One of our TBI patients, Heather, was given newfound hope from our stem cell treatments.  Two years after her initial injury, she was unable to talk or walk without assistance. Her doctors had told her they were unable to do anything more for her. We began stem cell treatments and her improvements have been miraculous. Her recovery is looking better each day since starting her stem cell treatments with us — so much so, that she even made a video recounting her stem cell journey at U.S. Stem Cell Clinic.

Another one of our patients, Barbara, was diagnosed with Multiple Sclerosis in 1988. Through our stem cell therapies and procedures, she gradually went from being wheelchair-bound to being able to stand up and do 50 squats on her own! As Barbara tells it, the first time her therapist saw her move her left side, she was astounded. Barbara and other MS patients have demonstrated promising improvements utilizing our regenerative medicine treatments.

On the business front, our financial indicators continue to trend positive with revenues up and liabilities down.  Here is a summary of U.S. Stem Cell’s most recent financial figures through Q2 2016:

  • Revenue up by 20% from $565K in Q2 2015 to $678K in Q2 2016.
  • Current liabilities down $2.7 million or 33% from $8.2M in Q2 2015 to $5.7M in Q2 2016.
  • Gross Margin improved from 41% in 2015 to 62% in 2016.
  • Cash used in operating activities decreased ($481K) or 74% from $646K in Q2 2015 to $165K in Q2 2016.
  • Working capital deficit improved by $2.5 million or 31.3% from $8M in Q2 2015 to $5.5M in Q2 2016.
  • Net loss improved 46% from $480K in Q2 2015 to $259K in Q2 2016.

We want to take this opportunity to thank our long-time shareholders and supporters as we develop pioneering regenerative medicine techniques.  We are working to bring regenerative therapies to the patients who need them.  We will continue to focus our efforts on new life-changing treatments. We invite you to follow us on social media for the latest updates and information about U.S. Stem Cell, Inc. and its divisions.

Warmest regards,

Mike Tomás

President & CEO

Read More

U.S. Stem Cell, Inc. Reports Positive Results for Q2 2016

Sunrise, FL – August 3, 2016 – U.S. STEM CELL, INC., a Florida corporation, (f/k/a/ Bioheart, Inc.) a leader in the regenerative medicine, cellular therapy industry providing physician based stem cell therapies to human and animal patients as well as a developer of novel autologous cell therapies, is pleased to highlight the following results from operations for the quarter ending June 30, 2016:

  • Revenue up by 20% from $565K in Q2 2015 to $678K in Q2 2016.
  • Current liabilities down $2.7 million or 33% from $8.2M in Q2 2015 to $5.7M in Q2 2016.
  • Gross Margin improved from 41% in 2015 to 62% in 2016.
  • Cash used in operating activities decreased ($481K) or 74% from $646K in Q2 2015 to $165K in Q2 2016
  • Working capital deficit improved by $2.5 million or 31.3% from $8M in Q2 2015 to $5.5M in Q2 2016
  • Net loss improved 46% from $480K in Q2 2015 to $259K in Q2 2016

“U.S. Stem Cell, Inc. continues to improve in its quarter-over-quarter P&L and balance sheet performance,” stated Mike Tomas, President and CEO of U.S. Stem Cell Inc. “Our mission to make a real and positive impact in the lives of the patients we are treating fuels our excitement for the future. We have become a world leader in the research of new treatments for patients with degenerative conditions and, with our physician partners, have jointly developed more than 30 protocols for their care. This passion moves us to continue to work hard to strengthen the health of our business and expand our care to more patients in need.”

Operating results for the three and six months ended June 30, 2016 are not necessarily indicative of the results that can be expected for the year ending December 31, 2016.

VIEW PDF HERE

About U.S. Stem Cell, Inc.

US Stem Cell, Inc. (formerly Bioheart, Inc.) is an emerging enterprise in the regenerative medicine / cellular therapy industry. We are focused on the discovery, development and commercialization of cell based therapeutics that prevent, treat or cure disease by repairing and replacing damaged or aged tissue, cells and organs and restoring their normal function. We believe that regenerative medicine / cellular therapeutics will play a large role in positively changing the natural history of diseases ultimately, we contend, lessening patient burdens as well as reducing the associated economic impact disease imposes upon modern society.

Our business, which includes three operating divisions (US Stem Cell Training, Vetbiologics and US Stem Cell Clinic) includes the development of proprietary cell therapy products as well as revenue generating physician and patient based regenerative medicine / cell therapy training services, cell collection and cell storage services, the sale of cell collection and treatment kits for humans and animals, and the operation of a cell therapy clinic. Management maintains that revenues and their associated cash in-flows generated from our businesses will, over time, provide funds to support our clinical development activities as they do today for our general business operations. We believe the combination of our own therapeutics pipeline combined with our revenue generating capabilities provides the Company with a unique opportunity for growth and a pathway to profitability.

Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate”, or “continue”, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Also, forward-looking statements represent our management’s beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

The Company is subject to the risks and uncertainties described in its filings with the Securities and Exchange Commission, including the section entitled “Risk Factors” in its Annual Report on Form 10-K for the year ended December 31, 2015, and its Quarterly Reports on Form 10-Q.

Read More

U.S. Stem Cell, Inc. Reports Positive Results for Q1 2016

Sunrise, FL – May 5, 2016 – U.S. STEM CELL, Inc., a Florida corporation, (f/k/a/ Bioheart, Inc.) a leader in the regenerative medicine, cellular therapy industry providing physician based stem cell therapies to human and animal patients as well as a developer of novel autologous cell therapies, is pleased to highlight the following results from operations for the quarter ending March 31, 2016:

  • Revenues increased $221,000 (45%) from $490,000 in Q1 2015 to $711,000 in Q1 2016,
  • Gross margins, primarily due to in-house versus subcontracted lab kit construction, increased to 78% in Q1 2016 from 40% in Q1 2015,
  • Net operating loss decreased ($794,000) (98%) from ($808,000) in Q1 2015 to ($14,000) in Q1 2016,
  • Overall net loss decreased ($685,000) (65%) from ($1,048,000) in Q1 2015 to ($363,000) in Q1 2016. The decrease is attributable to higher gross margins and a decrease in marketing and general and administrative expenses,
  • Cash used in operating activities decreased ($322,000) (84%) from ($384,000) in Q1 2015 to ($62,000) in Q1 2016. On a cash accounting basis, the Company generated $6,000 in positive cash flows, and
  • The Company’s current liabilities and working capital deficit remained, for the most part, constant from Q1 2015 to Q1 2016.

“U.S. Stem Cell, Inc. continues to improve in its quarter-over-quarter P&L and balance sheet performance,” stated Mike Tomas, President and CEO of U.S. Stem Cell Inc. “Our mission to make a real and positive impact in the lives of the patients we are treating fuels our excitement for the future. As awareness of our successful patient treatment outcomes expands, we look forward to all of our performance indicators turning positive. We thank our shareholders for the long-standing support and we look forward to reporting on our future successes.”

VIEW PDF HERE

About U.S. Stem Cell, Inc.

US Stem cell, Inc. (formerly Bioheart, Inc.) is an emerging enterprise in the regenerative medicine / cellular therapy industry. We are focused on the discovery, development and commercialization of cell based therapeutics that prevent, treat or cure disease by repairing and replacing damaged or aged tissue, cells and organs and restoring their normal function. We believe that regenerative medicine / cellular therapeutics will play a large role in positively changing the natural history of diseases ultimately, we contend, lessening patient burdens as well as reducing the associated economic impact disease imposes upon modern society.

Our business, which includes three operating divisions (US Stem Cell Training, Vetbiologics and US Stem Cell Clinic) includes the development of proprietary cell therapy products as well as revenue generating physician and patient based regenerative medicine / cell therapy training services, cell collection and cell storage services, the sale of cell collection and treatment kits for humans and animals, and the operation of a cell therapy clinic. Management maintains that revenues and their associated cash in-flows generated from our businesses will, over time, provide funds to support our clinical development activities as they do today for our general business operations. We believe the combination of our own therapeutics pipeline combined with our revenue generating capabilities provides the Company with a unique opportunity for growth and a pathway to profitability.

Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate”, or “continue”, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Also, forward-looking statements represent our management’s beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

The Company is subject to the risks and uncertainties described in its filings with the Securities and Exchange Commission, including the section entitled “Risk Factors” in its Annual Report on Form 10-K for the year ended December 31, 2014, and its Quarterly Reports on Form 10-Q.

Read More

CEO’s Blog: April 2016

Dear shareholders and friends,

U.S. Stem Cell Inc. continues to innovate and grow, making our mark in the regenerative medicine field by developing a number of therapies and products for patients suffering from degenerative conditions. Our three main operating divisions (U.S. Stem Cell Training, VetBiologics, and U.S. Stem Cell Clinic), focus on the development and commercialization of cell-based therapies that repair and replace damaged tissues, cells, and organs, restoring them to their normal functions.

Because of our dedication to the field, we have been able to help patients who previously had very few options available to them. We have had success helping patients with degenerative conditions, markedly demonstrated in our Traumatic Brain Injury patients who’ve shown great results.  We have not only been able to treat thousands of patients, but also have been actively involved in training physicians in our field, and have made meaningful contributions to international guidelines for stem cell research.

All of this would not be possible without our shareholders, partners, and dedicated team of practitioners. I would like to personally thank you all for your invaluable contributions and on-going support.

This month, we are pleased to announce a number of new developments.

We have recently launched our brand new website, which we hope will clearly guide you through the work that we do. This is part of our dedication to keeping you fully informed about our business operations and our continuing innovations in the field of stem cell research. Navigate through to learn about our products, board members, company news, financial summaries, and much more.

Our business strives to make its operations as efficient and cost effective as possible. In the most recent quarter, our company has succeeded in reducing its expenditures in operational activities, general and administrative tasks, and marketing strategies. An increase in banking services has meant that our Gross Margin from 2014 and 2015 has decreased. Despite this fact, we have seen a growth in revenue, as well as an improvement in our capital deficit, net loss, and current liabilities.

A summary of U.S. Stem Cell’s most recent financial figures through 4th quarter 2015:

Reductions in expenditure

  • Cash used in Q4 2015 down 85% or $306K.
    • From $361K in Q4 2014 to $55K in Q4 2015
  • Cash used in operating activities down $255k or 24%.
    • From $1.1M in 2014 to $845k in 2015
  • Marketing, general, and administrative expenses down $1.4M or 28.9%
    • From $4.7M in 2014 to $3.3M in 2015

General improvements

  • Current liabilities down by $3.1 million or 28%
    • From $11.1M in 2014 to $8.0M in 2015
  • Working capital deficit improved by $4.4 million or 40%
    • From $10,957,443 in 2014 to $6,583,569 in 2015

Profits and losses

  • Revenue up by 8%
    • From $2.06M in 2014 to $2.2M in 2015
  • Net loss improved 26% from $2.3M in 2014 to $1.7M in 2015
    • Gain on debt in 2014 of $2.5M, compared to gain of debt of $2.6M in 2015
  • Gross Margin down from 58.9% in 2014 to 32.9% in 2015, primarily due to increase in banking service

We invite you to follow us on social media for the latest updates and information about U.S. Stem Cell.

Warm Regards,

Mike Tomas

President & CEO

 

The information provided above is not be relied upon for the purchase or sale of our securities.  Please see our filings with the Securities and Exchange Commission (found at sec.gov).  In addition, this release is for informational purposes only and is not an offer to purchase or sell any of our securities. Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate”, or “continue”, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Also, forward-looking statements represent our management’s beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. The Company is subject to the risks and uncertainties described in its filings with the Securities and Exchange Commission, including the section entitled “Risk Factors” in its Annual Report on Form 10-K for the year ended December 31, 2015, and its Quarterly Reports on Form 10-Q.

Read More

Dr. William P. Murphy delivers Keynote Address at the Academy of Regenerative Practices

Sunrise, FL – February 9, 2016 – US STEM CELL, Inc. (OTCQB:USRM) – The chairman of the board of directors of US Stem Cell Inc, Dr. William P. Murphy, Jr., delivered the keynote address at the 2nd annual Academy of Regenerative Practices (www.regenerativeacademy.com) in Ft. Lauderdale, Florida this past weekend. A medical pioneer and founder of Cordis Corporation (now a Johnson & Johnson company), Dr Murphy is a medical doctor and inventor of medical devices including collaborating on a flexible sealed blood bag used for blood transfusions as well as patents for inventing the physiologic pace maker and the artificial kidney. He is the son of the American physician William Parry Murphy who shared the Nobel Prize in Physiology for Medicine in 1934, and Harriett Adams, the first licensed female dentist in Massachusetts.

Read More

U.S. Stem Cell Now Trading USRM; Completes Financing Transaction

Sunrise, FL – December 4, 2015 – US STEM CELL, Inc. (OTC: USRM) (f/k/a Bioheart, Inc.) a Florida corporation, a leader in the regenerative medicine, cellular therapy industry providing physician based stem cell therapies to human and animal patients as well as a developer of novel autologous cell therapies, is pleased to announce the completion of its name change with its new trading symbol – USRM. Additionally, the Company has completed a financing transaction with Magna Equities II, LLC (“Magna”).

Read More

U.S. Stem Cell Announces Positive Results for Traumatic Brain Injury (TBI) Patients

Sunrise, FL – December 3, 2015 – U.S. STEM CELL, Inc. (OTC: USRM), a Florida corporation, a leader in the regenerative medicine/cellular therapy industry, developer of novel autologous cell therapies, and provider of physician based stem cell therapies to human and animal patients, is pleased to announce that it has successfully completed five physician based treatments of traumatic brain injury (TBI) patients. The five patients, who received stromal vascular fraction from adipose tissue delivered intrathecally, have been treated over the past 12 months at the US Stem Cell Clinic located in Sunrise, FL

Read More

U.S. Stem Cell, Inc. Reports Positive Results for 3Q 2015

Sunrise, FL – November 5, 2015 – U.S. STEM CELL, Inc., a Florida corporation, (f/k/a/ Bioheart, Inc.) a leader in the regenerative medicine, cellular therapy industry providing physician based stem cell therapies to human and animal patients as well as a developer of novel autologous cell therapies, is pleased to highlight the following results from operations for the quarter ending September 30, 2015:

Read More

U.S. Stem Cell, Inc. (f/k/a/ Bioheart, Inc.) Receives FINRA Approval for Reverse Split and Name Change

Sunrise, FL – November 4, 2015 – U.S. STEM CELL, Inc., a Florida corporation, (f/k/a/ Bioheart, Inc.) a leader in the regenerative medicine, cellular therapy industry providing physician based stem cell therapies to human and animal patients as well as a developer of novel autologous cell therapies, is pleased to announce that it has received approval, effective today, from the Financial Industry Regulatory Authority (“FINRA”) to implement a reverse stock split in the ratio of 1 share for every 1,000 shares of its Common Stock. In connection with the Company’s reverse stock split, FINRA has assigned the Company a new stock symbol, BHRTD. The Company’s stock will be quoted as BHRTD through December 2, 2015, and thereafter, the trading symbol will be USRM (OTC Markets), reflecting the new name of the Company. The new CUSIP number is 90350U100. Additional information on the above transaction and name change can be found in our November 4, 2015 Form 8-K filing. Current stock certificates may be exchanged for new certificates by contacting the Company’s transfer agent, Continental Stock Transfer & Trust Company at:

Read More

US STEM CELL (Bioheart) Announces Insiders Intend to Purchase Company Common Stock in the Open Market

SUNRISE, FL / ACCESSWIRE / September 17, 2015 / US STEM CELL, Inc. (in transition from Bioheart, Inc. (BHRT.OB)) – announces today that “insiders” led by Dr. William P. Murphy, Jr., Chairman and Mike Tomas, President and CEO, intend to purchase, in the open market, up to 5% of the issued and outstanding Common Stock of the Company. The planned insider purchases are subject to customary restrictions based upon any of the participant’s knowledge of material non-public information and are further subject to federal securities disclosure rules. As the planed insider purchases are to be executed by individuals, US STEM CELL cannot guarantee the number of shares to be purchased or the time frame in which these shares will be bought in the open market.

Read More

For Immediate Release: Bioheart and Ascyrus Medical Execute Investment Agreement

Sunrise, FL – March 19, 2015 – Bioheart, Inc., a Florida Corporation (BHRT.OB) and Ascyrus Medical, LLC, a Florida Limited Liability Corporation are pleased to announce that they have entered into an investment agreement. The investment agreement provides for Bioheart to obtain a consolidating ownership stake in Ascyrus Medical upon the achievement of certain business milestones. Bioheart has through June 30, 2015 to meet its milestone obligations.

Read More

For Immediate Release: Bioheart Touts 2014 Accomplishments; Seeks More in 2015

Sunrise, FL – March 17, 2015 – Bioheart, Inc., a Florida Corporation (BHRT.OB),an emerging enterprise in the regenerative medicine / cellular therapy industry is pleased to announce, following the release of its Form 10-K Annual Report, key 2014 accomplishments including but not limited to:

Read More

For Immediate Release: Bioheart Strengthens Management Team with Appointment of Martin E. Schmieg as President of Vetbiologics, Inc.

Sunrise, FL – January 29, 2015 – Bioheart, Inc., a Florida Corporation (BHRT.OB), an emerging enterprise in the regenerative medicine / cellular therapy industry announced today the appointment of Martin E. Schmieg as President of Vetbiologics, Inc., the Company’s wholly owned animal health subsidiary.

Read More